Do analysts recommend XTLB or KZIA?

Novogen has a consensus target price of $27.33, indicating a potential upside of 122.04%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has stronger earnings and valuation, XTLB or KZIA?

XTL Biopharmaceuticals has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XTL Biopharmaceuticals $450K 12.00 -$6.97M -$0.64 N/A Novogen $30K 5,322.02 -$13.41M N/A N/A

Is XTLB or KZIA more profitable?

Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Novogen N/A N/A N/A

Do analysts rate LGVN or XTLB?

Longeveron currently has a consensus price target of $80.00, indicating a potential upside of 1,074.74%. Given Longeveron's stronger consensus rating and higher probable upside, equities analysts plainly believe Longeveron is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate XTLB or NXTC?

NextCure has a consensus price target of $19.00, suggesting a potential upside of 142.97%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is XTLB or NXTC more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A NextCure N/A -154.62% -100.19%

Do analysts recommend ALVR or XTLB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALVR or XTLB more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% XTL Biopharmaceuticals N/A N/A N/A

Do analysts prefer ALLR or XTLB?

Allarity Therapeutics currently has a consensus target price of $10.25, suggesting a potential upside of 621.83%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALLR or XTLB more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -152.77% -46.50% XTL Biopharmaceuticals N/A N/A N/A

XTL Biopharmaceuticals (XTLB) Competitors

$2.46 -0.05 (-1.80%)

As of 09/4/2026 03:57 PM Eastern

Compare

XTLB vs. KZIA, LGVN, NXTC, ALVR, and ALLR

Should you buy XTL Biopharmaceuticals stock or one of its competitors? XTL Biopharmaceuticals's main competitors and comparable companies include Novogen (KZIA), Longeveron (LGVN), NextCure (NXTC), AlloVir (ALVR), and Allarity Therapeutics (ALLR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does XTL Biopharmaceuticals compare to Novogen?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Novogen	N/A	N/A	N/A

XTL Biopharmaceuticals has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	12.00	-$6.97M	-$0.64	N/A
Novogen	$30K	5,322.02	-$13.41M	N/A	N/A

XTL Biopharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

Novogen has a consensus target price of $27.33, indicating a potential upside of 122.04%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Novogen had 8 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 8 mentions for Novogen and 0 mentions for XTL Biopharmaceuticals. Novogen's average media sentiment score of 0.24 beat XTL Biopharmaceuticals' score of 0.00 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Neutral
Novogen	Neutral

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Novogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Novogen beats XTL Biopharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Longeveron?

Longeveron (NASDAQ:LGVN) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

XTL Biopharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. XTL Biopharmaceuticals' return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
XTL Biopharmaceuticals	N/A	N/A	N/A

XTL Biopharmaceuticals has lower revenue, but higher earnings than Longeveron. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	18.10	-$22.70M	-$9.90	N/A
XTL Biopharmaceuticals	$450K	12.00	-$6.97M	-$0.64	N/A

Longeveron has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

Longeveron currently has a consensus price target of $80.00, indicating a potential upside of 1,074.74%. Given Longeveron's stronger consensus rating and higher probable upside, equities analysts plainly believe Longeveron is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 7.4% of Longeveron shares are owned by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Longeveron had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 1 mentions for Longeveron and 0 mentions for XTL Biopharmaceuticals. Longeveron's average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Longeveron	Neutral
XTL Biopharmaceuticals	Neutral

Summary

Longeveron beats XTL Biopharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to NextCure?

XTL Biopharmaceuticals (NASDAQ:XTLB) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

XTL Biopharmaceuticals' return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
NextCure	N/A	-154.62%	-100.19%

XTL Biopharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market.

In the previous week, NextCure had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 1 mentions for NextCure and 0 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.00 beat NextCure's score of -0.63 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Neutral
NextCure	Negative

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

XTL Biopharmaceuticals has higher revenue and earnings than NextCure. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	12.00	-$6.97M	-$0.64	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

NextCure has a consensus price target of $19.00, suggesting a potential upside of 142.97%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

XTL Biopharmaceuticals beats NextCure on 8 of the 14 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to AlloVir?

AlloVir (NASDAQ:ALVR) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

XTL Biopharmaceuticals has higher revenue and earnings than AlloVir. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
XTL Biopharmaceuticals	$450K	12.00	-$6.97M	-$0.64	N/A

XTL Biopharmaceuticals' return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
XTL Biopharmaceuticals	N/A	N/A	N/A

In the previous week, AlloVir's average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
XTL Biopharmaceuticals	Neutral

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

XTL Biopharmaceuticals beats AlloVir on 7 of the 10 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

XTL Biopharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
XTL Biopharmaceuticals	N/A	N/A	N/A

Allarity Therapeutics currently has a consensus target price of $10.25, suggesting a potential upside of 621.83%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XTL Biopharmaceuticals has higher revenue and earnings than Allarity Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	70.60	-$11.23M	-$0.78	N/A
XTL Biopharmaceuticals	$450K	12.00	-$6.97M	-$0.64	N/A

Allarity Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

In the previous week, Allarity Therapeutics' average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Allarity Therapeutics	Neutral
XTL Biopharmaceuticals	Neutral

Summary

XTL Biopharmaceuticals beats Allarity Therapeutics on 7 of the 13 factors compared between the two stocks.

Get XTL Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XTLB vs. The Competition

Export

Metric	XTL Biopharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.51M	$4.03B	$7.28B	$12.92B
Dividend Yield	N/A	3.60%	2.54%	8.90%
P/E Ratio	-3.84	12.65	272.43	25.42
Price / Sales	12.00	1,327.03	616.81	89.65
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	-20.46	16.15	12.85	6.17
Net Income	-$6.97M	-$22.76M	$3.47B	$349.50M
7 Day Performance	-0.61%	0.30%	0.97%	-0.15%
1 Month Performance	-13.86%	8.24%	5.46%	1.02%
1 Year Performance	N/A	49.08%	24.28%	14.50%

XTL Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XTLB XTL Biopharmaceuticals	0.576 of 5 stars	$2.46 -1.8%	N/A	N/A	$5.51M	$450K	N/A	N/A
KZIA Novogen	4.3459 of 5 stars	$14.60 +5.9%	$26.33 +80.4%	+52.2%	$22.80M	$42K	N/A	12	News Coverage Analyst Forecast
LGVN Longeveron	1.5039 of 5 stars	$0.70 +3.4%	$80.00 +11,274.9%	-9.0%	$21.68M	$1.20M	N/A	20
NXTC NextCure	2.9373 of 5 stars	$5.83 -1.4%	$19.00 +225.9%	+58.3%	$21.35M	N/A	N/A	90	News Coverage
ALVR AlloVir	N/A	$4.20 +2.4%	N/A	-13.8%	$21.18M	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XTLB) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. KZIA, LGVN, NXTC, ALVR, and ALLR

How does XTL Biopharmaceuticals compare to Novogen?

Summary

How does XTL Biopharmaceuticals compare to Longeveron?

Summary

How does XTL Biopharmaceuticals compare to NextCure?

Summary

How does XTL Biopharmaceuticals compare to AlloVir?

Summary

How does XTL Biopharmaceuticals compare to Allarity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. KZIA, LGVN, NXTC, ALVR, and ALLR

How does XTL Biopharmaceuticals compare to Novogen?

Is XTLB or KZIA more profitable?

Which has stronger earnings and valuation, XTLB or KZIA?

Which has more risk and volatility, XTLB or KZIA?

Do analysts recommend XTLB or KZIA?

Does the media favor XTLB or KZIA?

Do institutionals and insiders believe in XTLB or KZIA?

Summary

How does XTL Biopharmaceuticals compare to Longeveron?

Is LGVN or XTLB more profitable?

Which has preferable earnings & valuation, LGVN or XTLB?

Which has more volatility and risk, LGVN or XTLB?

Do analysts rate LGVN or XTLB?

Do insiders and institutionals believe in LGVN or XTLB?

Does the media prefer LGVN or XTLB?

Summary

How does XTL Biopharmaceuticals compare to NextCure?

Is XTLB or NXTC more profitable?

Which has more risk and volatility, XTLB or NXTC?

Does the media refer more to XTLB or NXTC?

Do insiders & institutionals believe in XTLB or NXTC?

Which has higher earnings & valuation, XTLB or NXTC?

Do analysts rate XTLB or NXTC?

Summary

How does XTL Biopharmaceuticals compare to AlloVir?

Which has more risk & volatility, ALVR or XTLB?

Which has higher earnings & valuation, ALVR or XTLB?

Is ALVR or XTLB more profitable?

Does the media favor ALVR or XTLB?

Do insiders and institutionals believe in ALVR or XTLB?

Do analysts recommend ALVR or XTLB?

Summary

How does XTL Biopharmaceuticals compare to Allarity Therapeutics?

Do insiders and institutionals believe in ALLR or XTLB?

Is ALLR or XTLB more profitable?

Do analysts prefer ALLR or XTLB?

Which has stronger earnings & valuation, ALLR or XTLB?

Which has more risk and volatility, ALLR or XTLB?

Does the media favor ALLR or XTLB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools